$3.25
−0.91%Sep 23, 2026, 21:51 UTC
Optimi Health Corp. completed and quality-released a production batch of 5mg naturally derived psilocybin capsules at its cGMP facility in Princeton, British Columbia, to supply a Health Canada-approved Phase 2 MDD trial and commercial customers in Australia.
Source:Sep 16, 2026, 12:25 UTC
Optimi Health expanded its clinical program with a Health Canada-authorized Phase 3 trial evaluating MDMA-assisted therapy for post-traumatic stress disorder in up to 100 veterans and frontline workers.
Source:Sep 10, 2026, 12:45 UTC
Optimi Health announced it will initiate a Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder, authorized by Health Canada, with dosing expected to be completed by the end of 2027.
Source:Jul 6, 2026, 19:53 UTC
Optimi Health shipped its third commercial psilocybin export to Australia.
Source:Jun 29, 2026, 13:00 UTC
Optimi Health completed the export of its 5mg psilocybin capsules to Australia for patients with treatment-resistant depression, marking its third commercial shipment since launching the product in September 2025.
Source:Jun 16, 2026, 16:37 UTC
Optimi Health Corp. launched two standardized microdose psilocybin finished drug products (1mg and 2mg) for clinical research.
Jun 10, 2026, 13:15 UTC
Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial.
Source:Jun 8, 2026, 12:00 UTC
Optimi Health secures ibogaine supply and commences finished drug product development for encapsulated dosages of 50mg and 100mg.
Source: